Talk about a shot in the arm (or a squirt up the nose): The ailing biotechnology sector got a boost last week when FDA advisory panels gave their blessings to a pair of potentially important but historically beleaguered drugs - Corixa Corp.'s Bexxar for non-Hodgkin's lymphoma and MedImmune Inc.'s FluMist, a nasal influenza vaccine. (BioWorld Financial Watch)